Pamela L. Kunz, MD | Authors


FDA-Approved Novel Agent Appears Promising in GEP-NETs

October 21, 2019

Pamela L. Kunz, MD, discusses the most recent FDA approval of Lutathera (lutetium [Lu 177] dotatate) for the treatment of patients with gastroenteropancreatic NETs (GEP-NETs), including foregut, midgut, and hindgut tumors.

Managing Diarrhea in Patients With Carcinoid Syndrome

October 20, 2017

Pamela L. Kunz, MD, assistant professor of medicine (oncology), Stanford University Medical Center, discusses managing the adverse event of diarrhea in patients with carcinoid syndrome, specifically with the use of telotristat ethyl (Xermelo) during the 10th Annual NANETS Symposium.